N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer

Figure 3 Verification of N-glycan peaks for distinguishing malignant pancreatic cancer (pancreatic ductal adenocarcinoma) from non-pancreatic ductal adenocarcinoma cases. A: N-glycan analysis in pancreatic ductal adenocarcinoma (PDAC) and non-PDAC (intraductal papillary mucinous neoplasm, mucinous cyst neoplasm, pancreatic neuroendocrine tumor, serous cyst adenoma, solid pseudopapillary neoplasm) groups; B: Tumor markers analysis in PDAC and non-PDAC groups. ^aP < 0.05, ^bP < 0.01. GPs: Glycan peaks; PDAC: Pancreatic ductal adenocarcinoma; SPN: Solid pseudopapillary neoplasm; PNET: Pancreatic neuroendocrine tumor; SCN: Serous cyst adenoma; IPMN: Intraductal papillary mucinous neoplasm; MCN: Mucinous cyst neoplasm; AFP: Alpha fetoprotein; CEA: Carcinoembryonic antigen; CA19-9: Cancer antigen 19-9.